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Antiobesity pharmacotherapy and programs/providers that possess weight management expertise are not commonly used by
physicians. The underlying reasons for this are not known. We performed a cross-sectional study in 33 Canadian medical practices
(36 physicians) examining 1788 overweight/obese adult patients. The frequency of pharmacotherapy use and referral for further
diet, exercise, behavioral management and/or bariatric surgery was documented. If drug treatment or referral was not made,
reasons were documented by choosing amongst preselected categories. Logistic regression models were used to identify predictors
ofantiobesitydruguse.Nosingleantiobesitymanagementstrategywasrecommendedbyphysiciansinmorethan50%ofpatients.
Referral was most common for exercise (49% of cases) followed by dietary advice (46%), and only 5% of eligible patients were
referred for bariatric surgery. Signiﬁcant predictors of initiating/continuing pharmacotherapy were male sex (OR 0.70; 95% CI
0.52–0.94), increasing BMI (1.02; 95% CI 1.01–1.03), and private drug coverage (1.78; 95% CI 1.39–2.29). “Not considered”
and “patient refusal” were the main reasons for not initiating further weight management. We conclude that both physician and
patient factors act as barriers to the use of weight management strategies and both need to be addressed to increase uptake of these
interventions.
1.Introduction
Excess body weight aﬀects 1.6 billion individuals globally
[1], is associated with substantial premature morbidity and
mortality [2, 3], impairs quality of life [4], and accounts for
2%–7% of direct healthcare spending in developed nations
[5]. Sixty-six % and 60% of the adult population in the US
and Canada, respectively, are overweight (body mass index
(BMI) ≥ 25kg/m2)o ro b e s e( B M I≥ 30kg/m2)[ 6, 7].
Despite the increasing recognition of obesity as a public
health problem and the well-documented beneﬁts of even
modest weight loss on comorbidities [7], there is concern
that obesity is underreported and undertreated by healthcare
professionals. Although weight loss counseling increases the
likelihood of attempted weight loss by 3-fold [8], only 43%
of obese participants in a nationally representative survey of
US adults reported receiving this intervention during their
annual checkup [9]. At odds with patient perceptions is the
ﬁnding that 75% of physicians report “always” or “nearly
always” administering weight management counseling to
their overweight or obese patients [10].
It also appears that, even among physicians who are
providing weight management counseling to their patients,
additional treatment options such as pharmacotherapy or
referral to an additional program or provider are often
not used [10, 11]. Weight management strategies such as2 Journal of Obesity
expert-led diet and exercise counseling, commercial weight
loss programs, pharmacotherapy, and behavioural therapy
are recommended by current guidelines [7], and each
can reduce weight by a clinically signiﬁcant amount (at
least 3%–5% of initial weight), which is associated with
improvements in cardiovascular risk factors [12–15]. A
recent study reported the following rates of referral/use:
dietician (67%), commercial weight loss program (59%),
exercise specialist (34%), and pharmacotherapy (29%) [10].
In a survey of 18 primary care practices in the US, only 14%
of overweight or obese patients received a referral for further
weight management [16].
Prior studies in this area have been retrospective in
nature and thus potentially subject to recall bias [10, 16].
They have also not attempted to examine underlying reasons
why physicians are not using these antiobesity management
strategies. This report details the major ﬁndings of the State
of Obesity Care in Canada Evaluation Registry (SOCCER)
study, which was designed to examine in closer detail
Canadian physicians’ use of antiobesity pharmacotherapy
and referral patterns to additional obesity management
programs and providers.
2. Methods
2.1.ParticipatingPracticesandPatientRecruitment. Registra-
tion in a provincial registry is a mandatory requirement for
all practicing physicians in Canada. Accordingly, provincial
medical registries were used to identify all primary care and
specialist physicians across Canada in 2005–2007. Approxi-
mately 2000 physicians were contacted by phone, fax and/or
E-mail, and the 50 physicians across 45 medical practices
thatagreedtoparticipateweresentstudymaterials,including
the study protocol, case report forms, and enrolment logs.
Physicians received telephone instructions describing the
proper procedure for recruiting patients and populating
study forms. This included reading through the entire study
form with the physician to ensure that accurate information
was collected for each question. No speciﬁc instructions
or education regarding weight management practices were
provided to the physicians. Thirty-six physicians from 33
of the 45 sites (27 primary care and 6 specialist practices)
recruited participants. The specialist practices consisted
of endocrinologists, cardiologists, and/or general internists
(whoprovideconsultativespecialtycarewithintheCanadian
health care system rather than primary care).
2.2. Inclusion and Exclusion Criteria. Consecutive patients
≥18 years with BMI levels ≥27kg/m2 who were able to
provide informed consent were eligible for inclusion. A BMI
threshold of 27kg/m2 was chosen instead of 25kg/m2 to
increase the likelihood that patients were truly overweight
(becauseBMIisanindirectmeasureofbodyfat)andbecause
this cutoﬀ is congruent with current recommendations for
initiating drug therapy [7]. Patients were also required to
have at least one indication for weight management, as
judged by their physician.
Consecutivesubjectsseenduringroutineclinicoperation
and identiﬁed on predeﬁned recruitment days were asked
to participate. A patient could only be enrolled once in the
study. Patients that were already participating in a clinical
trial, hospitalized, pregnant, nursing, or unable to attend
followup visits were excluded.
2.3. Assessment of Obesity Management Strategies. Because
each patient enrolled was deemed by the physician to require
weight management, it was assumed that the physician
would provide some counseling at the encounter. However,
no prior instructions were given to standardize the weight
management advice given. The focus of SOCCER was to
identify whether or not at this visit the physician initiated
or continued obesity pharmacotherapy for a given patient
and whether or not the physician referred the patient
for further weight management. If referral was made, the
type of weight management strategy or strategies involved
was recorded. The weight management strategies exam-
ined included dietary counseling, commercial weight loss
program/popular diet, exercise program (e.g., a trainer or
gym membership), behavioral therapy (e.g., psychologist),
and bariatric surgery. Depending on the strategy, referral
could take the form of explicit written communication
to another provider (e.g., surgery) or simply consist of
verbal instructions to the patient to seek a speciﬁc type of
treatment (e.g., commercial weight loss program). In the
case of bariatric surgery, data collection was limited to those
individuals considered potentially eligible for surgery (BMI
≥ 35kg/m2)[ 7].
Patients did not ﬁll out any forms; forms were populated
solely by physicians, and each physician was instructed to
consider each weight management strategy in sequence and
perform data entry in real time during the actual visit.
For pharmacotherapy, physicians were asked to indicate
if the patient will “start or continue pharmacotherapy
TODAY”. For the other weight management strategies, such
as dietary counseling, instructions to the physician read
as follows: “please indicate if you referred the patient
for Dietary Counseling as a weight management strategy
TODAY.” Demographic information, employment status,
medical history, physical examination, and current medica-
tions were also recorded at the time of the visit. In addition,
physicians were asked to document if the reason for the
referral was patient initiated and to provide the primary
reason if referral was not made for a given strategy, choosing
from the following categories (using check boxes): “patient
refused”, “not aﬀordable”, “not feasible”, “past treatment
failed”, “contraindicated”, and “not considered.”
2.4. Predictors of Antiobesity Drug Use. An additional goal
of SOCCER was to identify predictors of antiobesity drug
use. Covariate-adjusted, binary logistic regression models
were created to identify these predictors. Age, sex, BMI (per
unit increase), ethnicity, type of practice (primary care ver-
sus specialist), supplemental health insurance, employment
status (employed versus unemployed), gender concordance
between patients and physicians (concordant versus discor-
dant), and additional covariates that achieved a Wald Chi-
square P-value signiﬁcance level of .1 univariately were also
considered. The ﬁnal model was created using a backwardsJournal of Obesity 3
selection method to determine which of these additional
covariates contributed to the model at a Wald Chi-square
P-value of .1. Supplemental health insurance indicates the
presences of private health coverage, which is primarily
used to cover drug expenses. Sibutramine and orlistat are
not covered by Canadian provincial health care plans and
therefore patients typically pay out of pocket or through
private insurance for these medications.
2.5.DataCollectionandStatisticalAnalysis. Paper-basedcase
report forms were populated at point-of-care, faxed to the
project management centre (Population Health Research
Institute, McMaster University) and optically scanned using
DataFax(ClinicalDataFaxSystemsInc.,Hamilton,Ontario).
The forms were reviewed for missing, illegible, or contra-
dictory data input. All of the data management processes
followed written standard operating procedures (SOPs) and
conformed to Good Clinical Practice (GCP) standards for
the conduct and data management of clinical studies.
Statistical analysis was performed using SAS, version
9.1 (SAS Institute, Cary, NC). For all statistical tests, two-
tailed P values less than .05 were considered statistically
signiﬁcant. Survey methods (PROC SURVEYLOGISTIC)
account for the clustering of patients within individual
physician practices [17]. With the exception of one practice
that contained three physicians, only one physician per
practice participated in the study. Furthermore, in the multi-
physician practice, there were no diﬀerences in the use
of pharmacotherapy or referral practices among the three
physicians. Therefore, it was not necessary to control for
physician clustering within practices.
2.6. Ethics Approval. Ethics approval was obtained from
both the Canadian Shield Research Ethics Board and the
Research Ethics Board of McMaster University, Hamilton
Health Sciences.
2.7. Funding. SOCCER was funded by an unrestricted Grant
from Abbott Laboratories Canada. The design, conduct and
analysis of the study were carried out independently of the
study sponsor.
3. Results
3.1. Study Population and Comorbidities. Thirty-six physi-
cians enrolled 1904 patients across 33 participating sites in 7
provinces. 108 (5.7%) did not have an indication for obesity
management or meet age or BMI inclusion thresholds and
were excluded. Eight patients were excluded because of
missing BMI data, leaving 1788 patients included in the
ﬁnal analysis. Patients enrolled from specialty practices had
higher mean BMI levels and greater comorbidity compared
to patients seen in primary care practices (Table 1). The
most common comorbidities were hypertension (48%),
dyslipidemia (43%), osteoarthritis (27%), back pain (29%),
and type-2 diabetes (24%).
The percentage of patients with 0, 1, 2, 3, or >3
comorbidities was 14.2%, 17.6%, 16.0%, 16.5%, and 35.7%,
respectively.
3.2. Use of Pharmacotherapy and Referral for Other Obesity
Management Strategies. Pharmacotherapy was initiated or
continued in only 21% of cases (39% were by patient
request). The frequencies of referral for 0, 1, 2, or >2w e i g h t
management strategies (including use of pharmacotherapy)
were 29.0%, 22.8%, 26.2%, and 22.0%, respectively. Overall,
referral was most common for exercise, in 49% of cases,
followed by dietary advice, in 46% of cases. Only 5% of
eligible patients were referred for bariatric surgery (Table 2).
Predictors of initiating/continuing pharmacotherapy are
s u m m a r i z e di nT a b l e3. In the multivariable adjusted model,
male sex (OR 0.70; 95% CI 0.52–0.94) was associated with
a lower likelihood whereas increasing BMI (1.02; 95% CI
1.01–1.03) and private drug coverage (1.78; 95% CI 1.39–
2.29) were associated with a greater likelihood of initiating
or continuing antiobesity drug therapy.
3.3. Reasons for Lack of Referral. In all cases, physicians
listed “not considered” as the main reason for not using
pharmacotherapy (44% of cases) or not referring a patient
additional weight management (32%–65% of cases and
highest for bariatric surgery, Table 2). The second most
c o m m o nr e a s o no v e r a l lf o rl a c ko fr e f e r r a lw a sp a t i e n t
refusal and in the cases of referral for diet, exercise and
behavioral therapy, “not feasible” was also cited as a reason
in substantial minority of cases (Table 2). “Past treatment
failed”, “not aﬀordable”, and “contraindicated” were cited in
only a minority of cases.
4. Discussion
In summary, in this study of 36 physicians seeing nearly
1800 patients speciﬁcally identiﬁed as requiring weight
management, antiobesity pharmacotherapy was used in only
21% of cases. Furthermore, referral to additional weight
management provider or programs was recommended less
than 50% of the time. Physicians recorded “not considered”
and “patient refused” as the primary reasons for not using
these strategies.
The relatively low rates of use of pharmacotherapy
or referral for additional weight management have been
demonstrated in previous studies [8, 10], although three
major diﬀerences in the design of SOCCER compared to
previous studies are notable. First, only patients that, in the
mind of the physician, unequivocally required weight man-
agementwereenrolled.Second,physicianswereinstructedto
record data in real time to avoid recall bias and were aware
that they were being studied. Given these design factors,
one perhaps might have expected the prevalence of drug
therapyoruseofadditionalweightmanagementstrategiesto
be higher than that observed. Third, SOCCER also focused
on identifying the reasons for not using pharmacotherapy
or referring patients, and it is clear that the decision not to
proceed with these weight management strategies is related
tobothpatientandphysiciandecisions.Onlyinaminorityof
caseswerethesedecisionsbaseduponthepresenceofspeciﬁc
barriers such as cost. We also found that pharmacotherapy
was more likely to be initiated or continued in women,4 Journal of Obesity
Table 1: Baseline characteristics.
Overall
n = 1788
Primary care
n = 1300
Specialist
n = 488
P-value for specialist
versus primary care
Age, mean (SD), y 52.7 (14.3) 52.6 (14.6) 52.7 (13.6) .94
Weight, mean (SD), kg 100.6 (25.1) 95.8 (20.1) 113.6 (31.7) <.01
BMI, mean (SD), kg/m2 36.1 (7.9) 34.8 (6.3) 39.8 (10.2) <.01
Male 663 (37) 460 (35) 203 (41) .015
Caucasian 1614 (90) 1153 (89) 461 (95) <.01
Employed 987 (55) 737 (57) 250 (51) .04
Supplemental health insurance 996 (56) 715 (55) 281 (58) .33
Current smoker 245 (14) 189 (15) 56 (12) .09
Gout 75 (4) 45 (4) 30 (6) .02
Cancer 90 (5) 63 (5) 27 (6) .56
Polycystic ovarian syndrome 43 (2) 24 (2) 19 (4) .02
Type 2 diabetes 436 (24) 239 (18) 197 (40) <.01
Impaired fasting glucose/impaired
glucose tolerance 183 (10) 89 (7) 94 (19) <.01
Coronary artery disease 166 (9) 79 (6) 87 (18) <.01
Congestive heart failure 46 (3) 21 (2) 25 (5) <.01
Peripheral arterial disease 38 (2) 10 (1) 28 (6) <.01
Stroke 49 (3) 34 (3) 15 (3) .60
Arrhythmia 73 (4) 45 (4) 28 (6) .04
Dyslipidemia 760 (43) 518 (40) 242 (50) <.01
Hypertension 853 (48) 582 (45) 271 (56) <.01
Depression 395 (22) 261 (20) 134 (28) <.01
Anxiety 284 (16) 213 (16) 71 (15) .34
Eating Disorder 40 (2) 19 (2) 21 (4) <.01
Osteoarthritis 478 (27) 289 (22) 189 (39) <.01
Back Pain 526 (29) 347 (27) 179 (37) <.01
Fibromyalgia/chronic fatigue 88 (5) 69 (5) 19 (4) .21
Gall bladder disease 127 (7) 72 (6) 55 (11) <.01
Abnormal liver enzymes 60 (3) 26 (2) 34 (7) <.01
Gastrointestinal reﬂux 357 (20) 249 (19) 108 (22) .16
Incontinence 111 (6) 69 (5) 42 (9) .01
Sleep apnea 146 (8) 54 (4) 92 (19) <.01
Thrombosis/embolism 25 (1) 13 (1) 12 (3) .03
Data are expressed as no. (%) unless otherwise noted.
SD: standard deviation; BMI: body mass index.
heavier patients, and those with private drug coverage. This
sex diﬀerence is consistent with previous studies (both from
RCTs and population-based analyses of prescription ﬁlls)
[13, 18]. Furthermore, no antiobesity drug is covered under
a provincial drug plan in Canada; therefore, the drugs may
be unaﬀordable to many who do not have private coverage.
OnelimitationofSOCCERisthatfollowupprobesexam-
ining why the physician failed to consider pharmacotherapy
or referral or why the patient refused these actions were
not performed. It is certainly possible that physicians may
view such interventions as ineﬀective, may not be familiar
with their availability, or may expect that the patient can be
successful without further help. Physicians may be aware of
data demonstrating poor long-term persistence rates with
pharmacotherapy or may not view the beneﬁt/risk ratio of
current drugs to be favorable. A recent physician survey
reported that physicians might have unrealistic expectations
regarding how successfully patients can lose weight [10].
Weight losses of 38% were categorized as “a dream outcome”,
and 10% losses were viewed as “disappointing” despite data
demonstrating that such relatively small amounts of weight
loss can lead to clinically signiﬁcant beneﬁts including a
reduction in the incidence of type 2 diabetes in high-risk
patients [7, 19]. Conversely, patients may refuse help from
healthcare providers because they are more conﬁdent that
a self-directed weight management plan will be successful
[20]. Patients may also not view a physician’s oﬃce as
appropriate venue for weight management and may insteadJournal of Obesity 5
Table 2: Frequency of use of pharmacotherapy or referral for antiobesity management expertise.
Pharmacotherapy
used or referral
recommended
n (%)
Pharmacotherapy
not used or referral
not recommended
n (%)
Reason not recommended n (%)
Strategy All
By
patient
request
All
Patient-
related
reason
Patient
refused
Past
treatment
failed
Not
aﬀordable
Contra-
indicated
Not
feasible
Not
considered Missing
Pharmacotherapy 375 (21) 146 (39) 1413 (79) 792 (56) 491 (35) 47 (3) 167 (12) 63 (5) 24 (2) 618 (44) 3 (0.02)
Dietary counseling 813 (46) 257 (32) 974 (55) 614 (63) 300 (31) 86 (9) 39 (4) 9 (1) 180 (19) 343 (35) 17 (2)
Exercise training 866 (49) 291 (34) 920 (52) 573 (62) 216 (24) 37 (4) 57 (6) 18 (2) 245 (27) 297 (32) 50 (5)
Behavioral therapy 277 (16) 49 (18) 1508 (85) 713 (47) 404 (27) 28 (2) 49 (3) 2 (0.1) 230 (15) 720 (48) 75 (5)
Commercial
programs/popular
diets
261 (15) 97 (37) 1527 (85) 626 (41) 332 (22) 103 (7) 116 (8) 11 (1) 64 (4) 853 (56) 48 (3)
Obesity surgery
(BMI ≥ 35kg/m2) 41 (5) 24 (59) 742 (95) 227 (31) 134 (18) 4 (1) 16 (2) 12 (2) 61 (8) 482 (65) 33 (4)
Table 3: Predictors of initiating pharmacotherapy∗.
Variable Odds ratio (95% CI)
Age 0.98 (0.97–0.99)
Male 0.70 (0.40–1.23)
Body mass index 1.06 (1.03–1.08)
Caucasian ethnicity 1.52 (0.76–3.02)
Specialist physician 0.65 (0.21–2.0)
Private drug coverage 2.36 (1.52–3.66)
Currently employed 1.16 (0.82–1.66)
Patient-physician gender concordance 0.71 (0.34–1.48)
Current smoker 1.61 (1.13–2.30)
Gastroesophageal reﬂux disease 1.41 (0.97–2.05)
∗Multivariable ﬁnal adjusted model.
seek alternate methods. In addition, barriers to weight man-
agement may limit uptake of weight management strategies.
Many patient-related barriers have been identiﬁed, including
a lack of motivation, failure to recognize obesity as a
majorhealthcondition, time constraints,lowsocioeconomic
status, intimate saboteurs, and comorbid health conditions
(particularly psychological dysfunction and sleep disorders)
[21].
Bariatric surgery was recommended in only 5% of
eligible patients in SOCCER. Surgery is the only intervention
that consistently leads to substantial weight reduction, and
surgeryalsohasbeenassociatedwithreductionsinmortality;
improvements in quality of life, and has been shown to
be cost eﬀective at commonly cited thresholds. We theorize
that physicians may simply fail to consider surgery as
a viable treatment option or may be unaware of recent
evidence demonstrating that surgery substantially reduces
morbidity and mortality in severely obese patients [22].
Conversely, physicians may fail to consider surgery because
of the absence of a surgical program in their vicinity or
because of the extended (several years) wait times that
exist in Canadian surgical programs, although one would
have expected physicians to categorize this scenario as “not
feasible” rather than “not considered” [23].
Because volunteer physicians practices (only 2% of the
total number of practices contacted) within Canada were
enrolled in SOCCER, results may be subject to selection bias
andmaynotbegeneralizabletoallphysicianpracticeswithin
and outside this country. Compared to practices that were
not interested in participating, practices volunteering to take
partlikelyhadhigherlevelsofinterestandexpertiseinweight
management and may have been more likely to initiate
weight management strategies. Because the study speciﬁcally
entailed detailing antiobesity management strategies, partic-
ipants may also have been more likely to use management
strategies because they knew these were being measured (i.e.,
the Hawthorne eﬀect [24]). Therefore, it is probable that the
frequency of physician-initiated drug treatment or weight
management referral was overestimated compared to “usual
care” practices, and, therefore, our results may be considered
conservative.
In conclusion, we have demonstrated in this analysis of
Canadian physician practice patterns that rates of antiobe-
sity drug use and referral for additional weight manage-
ment strategies are low. In the majority of cases, either
physicians fail to consider these management strategies or
patients refuse them. If increased uptake of these guideline-
concordant strategies is to be achieved, both patients and
physician-related barriers to weight management will need
to be examined and addressed.
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